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Summary
Surgery remains the only radical treatment for colorectal cancer. However, with introduction of multidisciplinary 
teams and availability and advancement in all modes of treatments (surgical technique, technology and perioperative care, 
sistemic therapy and radiotherapy protocols), in more advanced stages the better disease control is achieved. In this article 
we outline primarily indications and considerations in surgical treatment mode.
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KIRUR[KO LIJE^ENJE KOLOREKTALNOG KARCINOMA
Sa`etak
Kirur{ko lije~enje je jedini kurativni pristup lije~enju kolorektalnog karcinoma. Ipak, uvo|enjem multidisciplinarnih 
timova i napretkom i dostupno{}u svih na~ina lije~enja (kirur{ka tehnika i tehnologija kao i perioperativna skrb za paci-
jenta, te napredak u sistemskoj i radioterapiji) u poodmaklim stadijima, su omogu}ili uspje{niju kontrolu bolesti. U ovom 
~lanku izosimo primarno indikacije i dileme kirur{kog na~ina lije~enja.
KLU^NE RIJE^I: kirurgija, kolorektalni karcinom, multidisciplinarni pristup
PRINCIPALS OF ONCOLOGIC SURGERY
Radical surgery with curative intent is the 
treatment of choice in colorectal cancer. The basic 
surgical principles are to remove the major tumor 
feeding vascular pedicle along with adjucent lym-
phatics while obtaining tumor-free margina, and 
en bloc resection of structures or organs invaded 
by the tumor.
In tumors in the cecum, ascending colon, he-
patic flexure, and proximal transverse colon, the 
right branch of the middle colic artery is ligated 
along with the right colic and the ileocolic arteries. 
If the middle colic artery is ligated at its origin, the 
extent of the resection of the bowel should be per-
formed to the distal third of the transverse colon. 
Tumors in the transverse colon may be resected 
by transverse colectomy or an extended right col-
ectomy incorporating cecum, ascending colon, he-
patic flexure, transverse colon, splenic flexure, 
and upper descending colon into the specimen. 
Descending and upper sigmoid colon cancers are 
resected with left hemicolectomy with ligation of 
the IMA at its origin from the aorta or by segmen-
tal resections. The continuity of colon is restored 
by either hand-sewn or stapled anastomosis. Good 
vascularization and no tension at the anastomosis 
are required to reduce leak and sepsis. The recom-
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mended margin for colon cancer is at least a 5-cm 
margin of normal bowel on oral and aboral side of 
the tumor. Rectal cancer requires the distal surgi-
cal margin of at least 2 cm in the fresh specimen, 
since it rarely has distal submucosal spread. In pa-
tients with low rectal adenocarcinomas (less than 
5 cm from the anal verge) at least a 1-cm margin of 
resection is required. Margins of less than 1 cm in 
patients who received neoadjuvant chemoradia-
tion and underwent sphincter-saving procedures 
may be obtained without compromising either re-
currence or disease-free survival (1). A set mini-
mum of 12 examined lymph nodes is required for 
accurate staging of node negative disease. How-
ever, smaller number of lymph nodes is often 
identified in rectal cancer after neoadjuvant treat-
ment and its significance is being discussed (1).
OBSTRUCTION AND PERFORATION
Obstruction or perforation and rectal bleed-
ing in colorectal cancer has a negative effect on 
survival (2). Moreover, emmergency setting and 
socioeconomic parameters also influence the out-
come (3). In case of obstruction (with or without) 
in colorectal cacner patients, two or three staged 
procedures are performed. On one hand, resection 
of the obstructing tumor and proximal ostomy 
may be performed. On the other hand, a diverting 
stoma (the first stage), then a colorectal cancer re-
section (second stage), and the occlusion of the os-
tomy (the third stage) may be performed. Finally, 
resection and continuity formation may be per-
formed in obstructing right-sided, distal transverse 
or splenic flexure carcinoma or when considering 
subtotal colectomy. The procedure must be tai-
lored based on the the patient performance status, 
the surgeon’s skills and the comorbidities (4).
CONTIGUOUS ORGAN INVOLVEMENT
Adherence to adjacent organs is often found 
in colorectal cancer patients. This may be to local 
tumor growth or secondary to perforation or fis-
tula formation. Mostly the colon cancer is adher-
ent to abdominal wall, stomach, duodenum, small 
bowel, ureters, urinary bladder, uterus, and ova-
ries, while rectal cancers invades uterus and vagi-
na, urinary bladder, sacrum or coccyx. The princi-
pal is to surgically remove the tumors en bloc 
without disturbing the adhesions. These adhe-
sions are malignant in nature in over 40% of the 
cases (5).
PERITONEAL DISEASE
Peritoneal carcinomatosis is encountered in a 
number of patients at diagnosis and it carries a 
poor prognosis. For these, after careful selection, 
some benefit may be derived from cytoreductive 
surgery combined with intraperitoneal chemo-
therapy (6,7).
RECTAL CANCER
Due to its anatomical specificities and loca-
tion within confined pelvic space and mostly ex-
traperitoneal locaclisation rectal cancer has a dif-
ferent treatment strategies than the rest of the co-
lon. Presently, combined-modality therapy greatly 
reduced, the risk of local and distant recurrence 
and improved overall survival. However, surgical 
resection remains the most important treatment 
mode. The rectum is divided in three parts by 
curves and distance form the anal verge. Tumors 
in proximal two thirds are resected by low anteri-
or resection. The lower rectum, however, could be 
resected with ultralow resection with/without di-
verting ileostomy or abdominoperineal extirpa-
tion. Only in emmergency setting or occationally 
after neoadjuvant treatment and in line with pa-
tient’s preferences Hartmann procedure is war-
ranted. Inoperable cases or obstructed cases 
planned for neoadjuvant treament receive a di-
verting ostomy. For all the procedures and their 
choice, multiple reports in the surgical literature 
correlate better stage-adjusted results in expert 
hands (8). The availability of adjuvant therapy en-
courages surgeons to be more aggressive in treat-
ment, including treatment of metastatic disease. 
As the local recurrence rate decreased to the teens 
with total mesorectal excision (TME), the practice 
of neo/adjuvant use of chemoradiation has been 
selectively decreased (9).
TOTAL MESORECTAL EXCISION (TME)
Total Mesorectal excision consists of sharp 
dissection of the space between the endopelvic 
fascia and the mesorectum. The mesorectum 
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should be removed with intact fascia propria and 
with preservation of the pelvic fascia and the au-
tonomic nerve plexus. This ensures the control of 
distal extramural spread and gaines free circum-
ferential margins. Discontiguous spread in the 
mesorectum varies from 5% to 64% for which 
lymph nodes are most responsible. Circumferen-
tial or radial margin involvement by tumor is a 
prognostic factor for both local and distant dis-
ease. The radial margin of excision can also serve 
as an indicator of the quality of the surgery, evalu-
ated by the pathologist after the resection (9).
EXTENDED LATERAL PELVIC NODE 
DISSECTION
Internal iliac node dissection is no longer rec-
ommended in rectal cancer surgery. Metastases to 
these lymph nodes occur in approximately 10% of 
patients and imply a poor prognosis. If clinically 
indicated, an attempt to remove these lymph 
nodes at the time of surgery is warranted(10).
RECURRENCES
Rectal salvage surgery for recurrences in-
cludes re-resection with a low anterior resection, 
abdominoperineal resection, pelvic exenterations 
(or its modifications), and, occasionally, extended 
sacral resections. If chemoradiation was not used 
during the management of the primary tumor, 
preoperative chemoradiation may be warranted 
prior to re-resection. It must be mentioned that 
these procedures are generally performed in con-
junction with urology, neurosurgery, and plastic 
surgery. If available, intraoperative radiotherapy 
should be strongly considered. After re-resection 
of isolated pelvic recurrences, there is a 15% 5-year 
survival (11). It cannot be overemphasized that 
these procedures carry a significant morbidity and 
mortality and should be performed by experi-
enced surgeons. Other forms of palliation should 
be considered prior to undertaking an aggressive 
surgical approach in a patient in whom cure will 
not be attainable.
SURGICAL PROGNOSIS
Advanced periopeative management greatly 
reduced perioperative morbidity and mortality 
(12). Despite the complementary sistemic and lo-
cal treatment, surgical results also depend on tu-
mor stage and its biologic behavior. Early colorec-
tal cancers (T1-2N0M0) can be cured with surgery 
alone. The 5-year survival for patients with stage 
II colorectal cancer is approximately 70%. Surgery 
alone in stages II and III rectal cancer carries a high 
failure rate; postoperative chemoradiation is war-
ranted if the patients were not treated with neoad-
juvant chemoradiation. Because the 5-year surviv-
al in stage II (T3N0M0) colon cancer patients is 
approximately 77% with surgery alone, adjuvant 
therapy is not widely recommended for these pa-
tients. As previously discussed, molecular mark-
ers may help in deciding adjuvant therapy for a 
subgroup of these patients. T4N0M0 colon cancer 
patients are at high risk of both local and distant 
recurrence and should be considered for adjuvant 
chemoradiation. Stage III colorectal cancer pa-
tients (any T N1-2 M0) have a 20% to 50% 5-year 
survival rate after surgery alone (13). It is in stage 
III colon cancer patients that adjuvant therapy has 
proven to be effective. Again, due to complemen-
tary mode of treatments many stage III and IV pa-
tients are downstaged and become elligable for 
surgical treatment, therefore multidisciplinary 
meetings after treatment evaluation are highly 
recommended.
FOLLOWUP AFTER PRIMARY THERAPY 
FOR COLORECTAL CANCER
Sixty percent to 80% of recurrences after cu-
rative intent surgery for colorectal cancer occurer 
within the first 2-years of therapy which requires 
an intensive follow up during that period. Con-
trols are usually scheduled every 3-6 months, and 
every six months after second year, yearly after 
five years. Follow up diagnostics at our Institution 
consists of CEA levels, imaging (abdominal US or 
chest X ray, and MR/CT abdomen and chest CT 
when indicated). Colorectal tumor recurrence is 
most common when the nodal involvement and 
tumor penetration beyond the bowel wall (T3 and 
T4 disease) are present. Differentiation and sub-
types of tumors are also prognostic factors for 
therapy failure (14,15). Moreover, resection of 
lower rectal cancers is technically more demand-
ing and wide negative margins due to physical 
anatomic restrictions may be difficult to obtain 
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which leads to a higher recurrence risk with lower 
tumors (16). In fact, there is an association with 
number of resected lymphnodes and favorable 
prognosis (17). Survival is also influenced by re-
gression rate after neoadjuvant terapy in rectal 
cancer (18). Finally, type of institution where the 
patient is treated- availability of multidisciplinary 
team- is important for the outcome(19).
The role of adjuvant chemoradiotherapy in 
colorectal cancer is well established by landmark 
Phase III trials that showed that concurrent chemo-
radiation improved survival in resected stages II 
and III rectal cancer() The recognition that 5-FU-
based alone or in combinations reduces distant 
failure risk led to the current standard of postop-
erative chemoradiation integrated with four cycles 
of adjuvant chemotherapy (with 5-FU and leucov-
orin). Adjuvant chemotherapy has traditionally 
been given for two months both before or six 
months after surgery, but this standard was em-
pirically established. Neoadjuvant radio/chemo-
radiation became the standard in rectal cancer af-
ter initial clinical staging on MRI. Its role in colon 
cancer is still a matter of debate.
CONCLUSION
The primary surgical resection of colorectal 
cancer is the only mode of treatment considered 
curative. However, for patients who had an inad-
equate surgical resection of the primary tumor or 
who had been downstaged and then resected, 
multimodal treatment including combination of 
surgery, sistemic and radiotherapy in various se-
quences, seem to be a good way to obtain disease 
control (21).
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